Freemont Management S.A. Sells 21,100 Shares of Boston Scientific Corporation $BSX

Freemont Management S.A. lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 88.3% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,800 shares of the medical equipment provider’s stock after selling 21,100 shares during the period. Freemont Management S.A.’s holdings in Boston Scientific were worth $273,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Steph & Co. purchased a new stake in Boston Scientific during the third quarter valued at approximately $25,000. Financial Consulate Inc. bought a new position in shares of Boston Scientific during the 3rd quarter valued at approximately $25,000. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $26,000. United Community Bank increased its holdings in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares in the last quarter. Finally, Kilter Group LLC bought a new stake in Boston Scientific during the 2nd quarter worth approximately $30,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.8%

Shares of BSX stock opened at $74.09 on Friday. The company’s fifty day simple moving average is $91.39 and its two-hundred day simple moving average is $97.90. Boston Scientific Corporation has a 52 week low of $72.69 and a 52 week high of $109.50. The stock has a market cap of $109.83 billion, a P/E ratio of 38.19, a PEG ratio of 1.02 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The business’s revenue was up 15.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on BSX shares. BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. Canaccord Genuity Group lowered their target price on shares of Boston Scientific from $131.00 to $112.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Royal Bank Of Canada cut their price target on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Finally, Robert W. Baird lowered their price objective on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $109.43.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.